DDInter1675 DDInter1435
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Simvastatin {u} (Compound) treats {v} (Disease) atherosclerosis
Simvastatin {u} (Compound) binds {v} (Gene) ABCC2
Simvastatin {u} (Compound) upregulates {v} (Gene) ANKRD10
Simvastatin {u} (Compound) downregulates {v} (Gene) PNP
Simvastatin {u} (Compound) causes {v} (Side Effect) Cataract
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liothyronine
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon alfacon-1
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Colchicine
Simvastatin (Compound) treats atherosclerosis (Disease)
Simvastatin (Compound) binds ABCC2 (Gene)
Simvastatin (Compound) upregulates ANKRD10 (Gene)
Simvastatin (Compound) downregulates PNP (Gene)
Simvastatin (Compound) causes Cataract (Side Effect)
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Liothyronine
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1
Simvastatin may lead to a major life threatening interaction when taken with Colchicine